yield. 13, 14 In the EBMT Handbook (chapter 6) it is stated that not more than 20 ml/kg donor wt should be aspirated. At our centre we never aspirate more than 15 ml/kg donor wt. Physicians' active during the BM-graft intensive years (before 2000) probably still have the skill whereas younger physicians have less experience. This may be a problem when the older physicians retire leaving a limited number of harvests to the younger ones. This was noted at our centre where the CD34 + yield decreased significantly when the most experienced physician retired. How shall we maintain the skill to harvest a good BM graft?
HSCT is a potentially curative treatment for many haematological malignancies and some non-malignant disorders. [1] [2] [3] In the early days of HSCT bone marrow (BM) was the only source of hematopoietic stem cells. However, during the last two decades a shift has occurred. Nowadays most transplant centres use more stem cells from peripheral blood (PBSC) than from BM. [4] [5] [6] As a consequence aspiration of BM has become a rather rare event for many physicians, especially at smaller centres. To obtain a "good" stem-cell rich BM harvest, an experienced physician with good aspiration technique is of outmost importance. As the number of BM aspirations has decreased dramatically during the last decades the logical consequence is that the opportunity to obtain this experience has decreased considerably. It has been shown previously that the number of CD34 + cells transplanted with the bone marrow graft impacts engraftment rate, NRM and survival.
7-10 So we asked the question whether the quality of the BM grafts and CD34 + cell dose has deteriorated during recent years? Furthermore, we wanted to investigate if there is any difference in quality (measured as relative content of CD34 + cells) and CD34 + cell dose between BM grafts aspirated at our centre for our own patients and BM grafts acquired from another centre where no connection exists between physician and patient.
To answer the first question we analysed the relative content of CD34 + cells in BM grafts given to patients undergoing HSCT at our centre between 1995 and 2011. For the second question we compared BM harvests performed at our centre (sibling donors) with harvests performed at other centres (URD). Total nucleated cell count and CD34 + cell count were analysed at Karolinska University Hospital. CD34 + cell enumeration was performed using a single platform flow cytometry analysis based on ISHAGE gating strategy.
The relative CD34 + cell counts were compared with MannWhitney's U-test or Kruskal-Wallis test. Factors affecting the CD34 + cell yield were analysed with multiple regression. The CD34 + cell dose (10 6 /kg patient) was also analysed in similar manner after removal of donor-patient pairs with a huge age or wt difference.
A total of 256 BM grafts aspirated at our and other centres were analysed and compared. The median (range) relative CD34 + cell content in these BM grafts was 1.07% (0.23-3.45). The material was divided into six 3-year periods. In the first period (1995-1997) the median CD34 + content was 1.57% compared with 1.01% in the last period, (2010-2011; Po0.001; Figure 1a) . The CD34 + cell dose/kg showed a similar pattern (Figure 1b) . This may indicate a probable deterioration in the skill in aspirating BM during the last years, also leading to a lower CD34 + cell dose/kg. It is known that the age of the donor also affects the CD34 + cell content. Median donor age was 30 years (1-63), 71 (27%) were younger than 20 years. According to our results grafts harvested from a donor younger than 20 years of age contains considerably higher yield of CD34 + cells, whereas the yield in older donors seems to be rather stable (Figure 1c ). For this reason we also studied the BM quality during the years only in donors aged older than 20 years. This analysis showed similar results as if all donors were included, 1.55% and 0.89% in the first and last period, P o 0.001. Do we care more for our own patients? BM grafts aspirated for our own patients had significantly higher CD34 + content and CD34 + cell dose/kg compared with grafts obtained from other centres (P o 0.00; Figures 2a and b) . To verify these results we performed multivariate analysis of factors affecting (i) the CD34 + cell content (%), and (ii) an insufficient CD34 + cell dose (o 3.0 × 10 6 /kg). Factors with significant effect on CD34 + cell content (%) were (analysis restricted to donors older than 20 years of age): year of harvest (RH 0.73, 95% confidence interval (CI) 0.62-0.85, P o 0.001), donor age (0.79, 0.67-0.92, P = 0.004) and "own patient" (1.20, 1.02-1.40, P = 0.026). Factors associated to an insufficient CD34 + cell dose/kg were (after removal of donor-patient pairs with a huge age or wt difference): patient wt (1.03, 1.01-1.05, P o 0.01) and year of harvest (1.27, 1.01-1.60, P = 0.04). This shows that the percentage of CD34 + cells in the graft has decreased and the risk to receive an insufficient graft has increased in recent years (Figure 2c ). Furthermore we showed that grafts aspirated at our hospital, for our own patients, contained higher percentage of CD34 + cells as opposed to imported grafts. We could not account for possible cell loss during transportation of cells obtained from other centres, but as we measure frequency of CD34+ cells and not absolute number we think this can be disregarded. We and others have shown that the cell loss because of storage and transportation is not significantly different between lymphocytes and CD34 + cells.
11,12
These results may indicate that as the number of BM harvests have decreased during recent years, the skill in how to aspirate a BM graft of good quality has decreased. When aspirating bone marrow, it is important to know that small volumes, 1 and no more than 3 ml, should be aspirated to get the best possible 
